<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2435">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05129462</url>
  </required_header>
  <id_info>
    <org_study_id>CONFIDENCE</org_study_id>
    <nct_id>NCT05129462</nct_id>
  </id_info>
  <brief_title>Consistency of PD-L1 Detecting Method Between E1L3N and 22C3 Monoclonal Antibodies in NSCLC Patients</brief_title>
  <acronym>CONFIDENCE</acronym>
  <official_title>Consistency of Immunohistochemical Detecting Assays Using E1L3N and 22C3 Monoclonal Antibodies for Detection of PD-L1 Expression in NSCLC Patients: A Prospective CONFIDENCE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hunan Province Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hunan Province Tumor Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluated the correlation between the qualitative test results of Xiamen Aide PD-L1 antibody&#xD;
      reagent (immunohistochemistry) and the efficacy of Keytruda single-agent therapy, and the&#xD;
      research data is used to support the registration and marketing of the assessment reagent&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 5, 2018</start_date>
  <completion_date type="Actual">October 1, 2021</completion_date>
  <primary_completion_date type="Actual">September 5, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Consistency</measure>
    <time_frame>August 2018- September 2021</time_frame>
    <description>the consistency of PD-L1 expression between monoclonal antibodies of E1L3N and 22C3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>August 2018- September 2021</time_frame>
    <description>Progression free survival time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>August 2018- September 2021</time_frame>
    <description>Objective response rate</description>
  </secondary_outcome>
  <enrollment type="Actual">52</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      tissue sample and plasma DNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with non-small cell lung cancer who have previously received single-agent K&#xD;
        therapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥18，advanced non-small cell lung cancer confirmed by histopathology, and have received&#xD;
             K-drug mono-therapy in the past, the return visit information is complete, with&#xD;
             traceable information such as tumor imaging examinations before and after treatment,&#xD;
             and the curative effect can be judged;&#xD;
&#xD;
          2. Able to provide FFPE samples with a storage life of 4 years: 6 slices of continuous&#xD;
             slices with a thickness of 3-5μm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pathological evaluation of the tissue sample has too few tumor cells (total number of&#xD;
             tumor cells &lt;100);&#xD;
&#xD;
          2. K-drug mono-therapy is neoadjuvant therapy or adjuvant therapy;&#xD;
&#xD;
          3. Other situations that the investigator thinks are not suitable for participating in&#xD;
             this clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongchang Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunan Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 10, 2021</study_first_submitted>
  <study_first_submitted_qc>November 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 20, 2021</last_update_submitted>
  <last_update_submitted_qc>November 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hunan Province Tumor Hospital</investigator_affiliation>
    <investigator_full_name>Yongchang Zhang</investigator_full_name>
    <investigator_title>Director, Head of Medical Oncology, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

